Groupama Asset Managment Trims Stock Position in Abbott Laboratories $ABT

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment lowered its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 15.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,466 shares of the healthcare product maker's stock after selling 12,112 shares during the quarter. Groupama Asset Managment's holdings in Abbott Laboratories were worth $8,433,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Van Lanschot Kempen Investment Management N.V. raised its holdings in shares of Abbott Laboratories by 2.7% in the 1st quarter. Van Lanschot Kempen Investment Management N.V. now owns 67,825 shares of the healthcare product maker's stock valued at $8,997,000 after buying an additional 1,766 shares during the period. JT Stratford LLC purchased a new stake in shares of Abbott Laboratories in the 1st quarter valued at $1,244,000. Berkshire Asset Management LLC PA raised its holdings in shares of Abbott Laboratories by 1.2% in the 1st quarter. Berkshire Asset Management LLC PA now owns 308,390 shares of the healthcare product maker's stock valued at $41,324,000 after buying an additional 3,742 shares during the period. Legacy Financial Advisors Inc. raised its holdings in shares of Abbott Laboratories by 8.3% in the 1st quarter. Legacy Financial Advisors Inc. now owns 10,337 shares of the healthcare product maker's stock valued at $1,371,000 after buying an additional 794 shares during the period. Finally, bLong Financial LLC raised its holdings in shares of Abbott Laboratories by 2.1% in the 1st quarter. bLong Financial LLC now owns 7,257 shares of the healthcare product maker's stock valued at $963,000 after buying an additional 150 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABT. BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Royal Bank Of Canada boosted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Mizuho boosted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Finally, Morgan Stanley boosted their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Abbott Laboratories Stock Up 0.3%

Shares of NYSE:ABT traded up $0.4120 on Friday, hitting $132.4120. 4,130,154 shares of the company's stock were exchanged, compared to its average volume of 5,721,513. The firm's 50-day moving average is $131.08 and its 200 day moving average is $131.29. The company has a market capitalization of $230.46 billion, a PE ratio of 16.59, a P/E/G ratio of 2.50 and a beta of 0.70. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were given a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio is 29.57%.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.